Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | 453.31%1.71M | 9,865.36%700.76K | 112.06%290.8K | 295.24%238.41K | 359.05%479.86K | 70.73%309.02K | -92.08%7.03K | 137.13K | 60.32K | 104.53K |
Other taxes | ---- | ---- | ---- | ---- | 2,432.85%50.66K | ---- | ---- | ---- | ---- | --2K |
Other operating expenses | 453.31%1.71M | 9,865.36%700.76K | 112.06%290.8K | 295.24%238.41K | 318.60%429.2K | 70.73%309.02K | -92.08%7.03K | --137.13K | --60.32K | --102.53K |
Operating profit | -453.31%-1.71M | -9,865.36%-700.76K | -112.06%-290.8K | -295.24%-238.41K | -359.05%-479.86K | -70.73%-309.02K | 92.08%-7.03K | -137.13K | -60.32K | -104.53K |
Net non-operating interest income expense | 3.53M | 820.42K | 915.96K | 931.43K | 858.25K | 0 | 0 | 0 | 0 | 0 |
Non-operating interest income | --3.53M | --820.42K | --915.96K | --931.43K | --858.25K | --0 | --0 | --0 | --0 | --0 |
Other net income (expense) | 306.14K | 4.92K | 28.14K | -33.05K | 306.14K | |||||
Gain on sale of security | --11.14K | --4.92K | --28.14K | ---33.05K | --11.14K | ---- | ---- | ---- | ---- | ---- |
Special income (charges) | --295K | --0 | --0 | --0 | --295K | --0 | --0 | --0 | --0 | --0 |
-Less:Other special charges | ---295K | --0 | ---- | ---- | ---295K | ---- | ---- | ---- | ---- | ---- |
Income before tax | 786.81%2.12M | 1,871.43%124.57K | 576.39%653.29K | 1,194.11%659.97K | 754.85%684.53K | -70.73%-309.02K | 92.08%-7.03K | -137.13K | -60.32K | -104.53K |
Income tax | 330,427.43%746.54K | 75,154.42%169.62K | 187.76K | 178.04K | 211.12K | -226 | -226 | 0 | 0 | 0 |
Net income | 545.55%1.38M | -562.00%-45.06K | 439.47%465.53K | 898.95%481.93K | 552.89%473.42K | -70.60%-308.79K | 92.33%-6.81K | -137.13K | -60.32K | -104.53K |
Net income continuous Operations | 545.55%1.38M | -562.00%-45.06K | 439.47%465.53K | 898.95%481.93K | 552.89%473.42K | -70.60%-308.79K | 92.33%-6.81K | ---137.13K | ---60.32K | ---104.53K |
Minority interest income | ||||||||||
Net income attributable to the parent company | 545.55%1.38M | -562.00%-45.06K | 439.47%465.53K | 898.95%481.93K | 552.89%473.42K | -70.60%-308.79K | 92.33%-6.81K | -137.13K | -60.32K | -104.53K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 545.55%1.38M | -562.00%-45.06K | 439.47%465.53K | 898.95%481.93K | 552.89%473.42K | -70.60%-308.79K | 92.33%-6.81K | -137.13K | -60.32K | -104.53K |
Basic earnings per share | ||||||||||
Diluted earnings per share | ||||||||||
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |